dld-1 Antibody

What are the fundamental characteristics of DLD-1 cells that make them valuable for antibody research?

DLD-1 is a human colorectal adenocarcinoma cell line derived from a colon tumor of a 65-year-old male patient with Dukes' type C colorectal cancer. These epithelial cells display several key characteristics relevant to antibody research. They have a pseudodiploid karyotype (2n = 46) and express various oncogenes including C-Myc, KRAS, HRAS, and NRAS, as well as p53 protein .

These cells exhibit adherent growth in culture with a doubling time of approximately 48 hours. Notably, DLD-1 cells possess strong migration and invasion capabilities, making them particularly useful for evaluating antibodies targeting metastatic processes . Their well-defined molecular profile provides a consistent baseline for assessing antibody specificity and efficacy in colorectal cancer research.

Additionally, DLD-1 cells have been instrumental in studies evaluating PD-L1-targeted therapies and immune checkpoint inhibitors, suggesting they either naturally express relevant immune checkpoint molecules or can be modified to do so .

What are the optimal culture conditions for maintaining DLD-1 cells in antibody research applications?

For consistent and reproducible antibody research, DLD-1 cells require specific culture conditions. They should be maintained in RPMI 1640 medium supplemented with 2mM glutamine and 10% fetal bovine serum (FBS). Cultures should be kept at 37°C in an atmosphere containing 95% air and 5% CO₂ .

The recommended subculturing protocol involves:

• Removing and discarding culture medium

• Briefly rinsing the cell layer with 0.25% trypsin-0.53mM EDTA solution

• Adding 2.0-3.0 mL of trypsin-EDTA solution and observing until cell dispersion (typically 5-15 minutes)

• Adding 6.0-8.0 mL of complete growth medium and gently pipetting

• Transferring appropriate aliquots to new culture vessels

• Incubating at 37°C

Medium should be renewed 2-3 times weekly, with a subcultivation ratio of 1:3 to 1:10 recommended. For cryopreservation, DLD-1 cells should be frozen in a mixture containing 70% medium, 20% FBS, and 10% DMSO, then stored at -196°C for long-term viability .

How can researchers confirm the authenticity and quality of DLD-1 cells for antibody testing?

Before conducting antibody research with DLD-1 cells, researchers should verify cell line authenticity and quality through multiple approaches:

First, confirm cell morphology through microscopic examination. DLD-1 cells should display epithelial morphology with adherent growth characteristics .

Perform karyotype analysis to verify the pseudodiploid chromosome complement (2n = 46) . Short tandem repeat (STR) profiling should be conducted to authenticate the genetic profile against established databases.

Mycoplasma testing is essential, as contamination can significantly affect experimental outcomes. DLD-1 cultures should test negative for mycoplasma as indicated in the cell line specifications .

Additionally, viral testing should be performed to ensure cultures are negative for common contaminants. The standard testing panel includes EBV, HBV, HCV, HHV-8, HIV-1, HIV-2, HTLV-1/2, MLV, and SMRV .

Expression of key markers should be verified, particularly those relevant to your antibody research. DLD-1 cells typically express p53 protein and various oncogenes (C-Myc, KRAS, HRAS, NRAS) , which can be confirmed through Western blot or immunostaining methods.

How should researchers generate modified DLD-1 cell lines for evaluating antibody specificity?

Generating genetically modified DLD-1 cells provides powerful tools for evaluating antibody specificity and efficacy. CRISPR-Cas9 technology offers a robust approach for creating knockout or knockin variants. The following methodology has been successfully applied for creating DLD-1 EREG knockout lines:

• Design sgRNAs targeting your gene of interest (e.g., EREG)

• Clone the sgRNA into a lentiviral CRISPR vector (e.g., lentiCRISPRv2-hygro)

• Produce lentivirus particles by co-transfecting 293T cells with the CRISPR construct and packaging plasmids (psPAX2 and pMD2.G) using an appropriate transfection reagent like Fugene HD

• Transduce DLD-1 cells with the lentiviral particles

• Select transduced cells using the appropriate antibiotic (e.g., 50 μg/ml hygromycin for lentiCRISPRv2-hygro)

• Perform clonal selection to isolate pure knockout populations

• Validate knockout efficiency through Western blotting or other protein detection methods

This approach creates isogenic cell line pairs (parental and knockout) that differ only in the expression of your target protein, providing an ideal system for rigorously evaluating antibody specificity. When testing antibodies, the knockout line serves as a negative control - a specific antibody should show differential binding between wild-type and knockout cells.

What co-culture systems can effectively evaluate antibody-mediated immune cell killing of DLD-1 cells?

Co-culture systems offer valuable insights into antibody-mediated immune killing of DLD-1 cells. Based on established methodologies, researchers should implement the following approach:

First, prepare DLD-1 target cells by seeding them 24 hours before co-culture to allow attachment and establishment of a monolayer. For immune effector cells, freshly isolated peripheral blood mononuclear cells (PBMCs) are commonly used. The experimental design should include various effector-to-target (E:T) ratios to determine optimal conditions .

When setting up the co-culture, add PBMCs to pre-established DLD-1 monolayers at the predetermined E:T ratios. Include experimental antibodies at appropriate concentrations - for instance, 0.5 μg/mL has been used for testing constructs like anti-PD-L1:TRAIL . Include necessary controls such as non-targeting antibodies or bispecific antibody controls (e.g., anti-EpCAM:anti-CD3 bispecific antibody has been used at 50 ng/mL) .

After the co-culture period (typically 24-48 hours), carefully wash away non-adherent cells and quantify cancer cell viability. This can be done using MTS assays for adherent viable cells, or through flow cytometry-based methods like Annexin-V staining to assess apoptosis .

Additionally, analyze the co-culture supernatants for immune activation markers such as IFNγ secretion using ELISA, which provides insight into T cell activation in response to the therapeutic antibody .

What methodological approaches should be used to evaluate antibody-induced signaling changes in DLD-1 cells?

To rigorously evaluate antibody-induced signaling changes in DLD-1 cells, researchers should implement a comprehensive methodological framework that captures both immediate and delayed signaling events:

For immediate signaling events, prepare DLD-1 cells by serum-starving them in low serum media (e.g., 0.5% FBS in RPMI) for 3-6 hours to reduce baseline signaling activity. Treat the cells with the antibody of interest at appropriate concentrations, including controls such as PBS (negative) and recombinant ligand (positive). The search results mention using 15 μg/ml of test antibody (H231 mAb) or control antibody (cmAb) and 300 ng/ml of recombinant ligand (hEREG) .

Harvest cells at specific time points (5 minutes for rapid signaling events, then 15, 30, 60 minutes, and longer time points as needed) to capture the temporal dynamics of signaling. Process samples for Western blot analysis to detect phosphorylation of relevant signaling proteins. The search results describe examining PARP cleavage to assess apoptotic signaling following antibody treatment .

For pathway-specific analysis, use selective inhibitors of relevant signaling pathways in combination with antibody treatment to establish pathway dependence. Include phospho-specific antibodies for key nodes in signaling cascades (MAPK, AKT, STAT pathways) in your Western blot analysis.

Complementary approaches should include quantitative PCR to measure changes in gene expression following antibody treatment, and multiplex phospho-protein assays for higher-throughput signaling analysis across multiple pathways simultaneously.

How can researchers effectively evaluate antibody internalization kinetics in DLD-1 cells?

Evaluating antibody internalization kinetics in DLD-1 cells requires sophisticated methodological approaches that accurately capture the temporal dynamics of this process. Researchers should implement the following protocol:

Begin by fluorescently labeling the antibody of interest using pH-sensitive dyes that change emission properties upon internalization into acidic endosomal/lysosomal compartments. Alternatively, use standard fluorophores for basic internalization studies.

For quantitative analysis, incubate DLD-1 cells with labeled antibody at 4°C for 30-60 minutes to allow binding without internalization. After washing to remove unbound antibody, shift cells to 37°C to initiate internalization. At various time points (5, 15, 30, 60, 120 minutes), process cells for analysis using one of two approaches:

• Acid wash method: Treat cells with acidic buffer (pH 2.5-3.0) to strip remaining surface-bound antibody, then measure internalized (acid-resistant) fluorescence by flow cytometry or fluorescence microscopy.

• Quenching method: Add membrane-impermeable fluorescence quenchers to eliminate signal from surface-bound antibodies, leaving only internalized antibody signal detectable.

For detailed trafficking studies, perform confocal microscopy with co-localization markers for different cellular compartments. Co-stain with markers for early endosomes (EEA1), late endosomes (Rab7), lysosomes (LAMP1), and recycling endosomes (Rab11) to map the intracellular fate of the antibody.

This approach is particularly important for antibody-drug conjugate development, as the search results emphasize that an ideal ADC target should rapidly internalize and traffic to the lysosome for payload release .

What are the optimal protocols for evaluating antibody biodistribution using DLD-1 xenograft models?

For evaluating antibody biodistribution in DLD-1 xenograft models, immunoPET imaging combined with ex vivo biodistribution analysis provides comprehensive data. Based on established methodologies, researchers should follow this protocol:

Begin by establishing DLD-1 xenografts through subcutaneous implantation of 2.5 × 10^6 DLD-1 cells in 50% Matrigel into the lower right flank of immunodeficient mice (e.g., nu/nu mice). Allow tumors to grow until they reach 4-6 mm in diameter .

For antibody radiolabeling, conjugate the test antibody and an isotype-matched control antibody with desferrioxamine (DFO) via lysine conjugation. Radiolabel the DFO-antibody conjugates with zirconium-89 (^89Zr), aiming for a radiochemical purity >95% .

Administer 200 μg of radiolabeled antibody (containing 139-215 μCi of ^89Zr) intravenously to tumor-bearing mice. Perform PET/CT imaging at multiple time points, with 5 days post-injection being optimal for most antibodies to allow sufficient blood clearance while maintaining tumor signal .

Acquire images using a small animal PET/CT scanner and analyze them to determine tumor-to-muscle ratios, which provides a quantitative measure of specific tumor targeting .

Following the final imaging session, perform ex vivo biodistribution analysis:

• Euthanize the animals and resect relevant organs and tissues

• Weigh each tissue sample

• Measure radioactivity using a gamma counter

• Calculate the percentage of injected dose per gram of tissue (%ID/g) for each sample

This combined approach provides both visual and quantitative data on antibody distribution, enabling comprehensive evaluation of tumor targeting efficiency and potential off-target accumulation.

How can DLD-1 cells be utilized to develop and evaluate bifunctional antibodies for cancer immunotherapy?

DLD-1 cells provide an excellent platform for developing and evaluating bifunctional antibodies that combine multiple therapeutic mechanisms. Based on successful approaches with bifunctional constructs like anti-PD-L1:TRAIL, researchers should implement the following methodology:

Begin by characterizing target expression on DLD-1 cells or, if necessary, engineer DLD-1 cells to express the targets of interest. For instance, DLD-1.PD-L1 cells have been created to evaluate PD-L1-targeting bifunctional antibodies .

For evaluating bifunctional antibodies that combine immune checkpoint inhibition with direct tumor killing (like anti-PD-L1:TRAIL), design experiments that assess each function separately:

• For immune checkpoint blocking activity:

  • Pre-incubate DLD-1.PD-L1 cells with the bifunctional antibody

  • Wash cells and incubate with the receptor protein (e.g., PD-1:Fc)

  • After washing, detect bound receptor with labeled secondary antibodies

  • Quantify by flow cytometry to determine blocking efficiency

• For direct tumor-killing activity:

  • Treat DLD-1 cells with the bifunctional antibody at various concentrations

  • Measure cell death through appropriate assays (Annexin-V staining, PARP cleavage analysis)

  • Include controls such as monofunctional antibodies that target only one component

• For combined activity in an immunotherapy context:

  • Establish co-cultures of DLD-1 cells with immune effector cells (PBMCs or isolated T cells)

  • Add the bifunctional antibody and appropriate controls

  • After incubation (24-48 hours), assess both tumor cell death and immune cell activation

  • Measure IFNγ secretion by ELISA to evaluate T cell activation

This comprehensive evaluation allows researchers to understand how the bifunctional antibody's components work individually and synergistically, providing crucial insights for optimizing these complex therapeutic agents.

How should researchers address variable target expression in DLD-1 cells when evaluating antibody efficacy?

Variability in target expression presents a significant challenge for antibody efficacy studies with DLD-1 cells. Researchers should implement the following methodological approach to address this issue:

First, quantify baseline target expression in your DLD-1 culture using flow cytometry, Western blotting, or immunofluorescence. This establishes a reference point for all subsequent experiments. Create standardized expression conditions through cytokine treatment when appropriate. For instance, IFNγ treatment upregulates PD-L1 expression on cancer cells, providing a more consistent target level for anti-PD-L1 antibodies .

Generate stable cell lines with controlled target expression using lentiviral transduction or CRISPR-mediated gene editing. This creates isogenic cells with defined expression levels, as seen with DLD-1.PD-L1 cells mentioned in the search results .

When conducting antibody efficacy studies, incorporate a target expression analysis within each experiment to correlate efficacy with expression levels. This allows normalization of results based on actual target availability.

Use a panel of DLD-1-derived lines with varying target expression levels to establish dose-response relationships across expression ranges. This provides insight into how expression levels influence antibody efficacy thresholds.

For therapeutic antibodies relying on immune cell engagement, the co-culture system described previously (mixing DLD-1 cells with PBMCs at defined E:T ratios) becomes especially valuable, as it can reveal how target expression influences immune-mediated killing efficiency .

By implementing these approaches, researchers can generate more reliable and reproducible data that accounts for the inherent variability in target expression across experiments.

What controls are essential for validating antibody specificity in DLD-1 experimental systems?

Rigorous validation of antibody specificity in DLD-1 experimental systems requires a comprehensive set of controls. Researchers should implement the following controls to ensure reliable data interpretation:

• Genetic knockout controls: Generate DLD-1 cells with CRISPR-mediated knockout of the target antigen. These cells provide the gold standard negative control for specificity testing. The search results describe generating DLD-1 EREG KO cells that serve this purpose .

• Isotype-matched control antibodies: Include control monoclonal antibodies (cmAb) of the same species and isotype as the test antibody but without relevant target binding. The search results mention cmAb controls used alongside test antibodies .

• Competitive binding controls: Pre-incubate DLD-1 cells with excess unlabeled antibody before adding the labeled test antibody. Specific binding should be competitively inhibited, while non-specific binding will remain.

• Vector control cells: When using engineered DLD-1 cells, include "vector only" controls that have undergone the same engineering process but without the target gene. The search results note that "H231 failed to bind vector cells, verifying specificity" .

• Blocking controls with recombinant proteins: Pre-block target proteins with recombinant ligands or binding partners. The search results describe neutralization experiments using recombinant hEREG to verify antibody specificity .

• Cross-reactivity panel: Test antibodies on multiple cell lines with variable expression of the target antigen. The search results mention testing H231 antibody on both DLD-1 and LoVo cells, demonstrating binding specificity across different cellular contexts .

• Secondary reagent controls: Include samples treated only with secondary detection reagents to assess background signal or non-specific binding of the detection system.

By implementing this comprehensive control framework, researchers can conclusively demonstrate antibody specificity and distinguish true binding events from experimental artifacts.

How should researchers analyze and interpret data from DLD-1 xenograft studies evaluating antibody targeting?

Begin by calculating standardized uptake values (SUVs) from PET imaging data, normalizing for injected dose and animal weight to enable cross-study comparisons. Determine tumor-to-background ratios, particularly tumor-to-muscle ratios as mentioned in the search results . Higher ratios indicate more specific targeting.

Perform region-of-interest (ROI) analysis on PET images to quantify uptake in tumors and reference tissues. Generate time-activity curves if multiple imaging time points were acquired to understand the kinetics of antibody accumulation and clearance.

For ex vivo biodistribution data, calculate the percentage of injected dose per gram of tissue (%ID/g) for each organ and the tumor . Compare uptake in DLD-1 tumors to normal tissues to determine the specificity index (tumor uptake divided by normal tissue uptake). Higher indices indicate more selective targeting.

Always compare test antibody data to an isotype-matched control antibody (cmAb) tested under identical conditions . The differential uptake between specific and non-specific antibodies provides the most reliable measure of true target-mediated localization.

Correlate imaging and biodistribution data with tumor characteristics determined by post-mortem analysis:

• Target expression levels measured by immunohistochemistry

• Vascular density that might affect antibody delivery

• Necrotic fractions that could influence apparent targeting efficiency

Apply appropriate statistical analyses to determine significance of observed differences. For small animal studies, paired t-tests or non-parametric alternatives are typically appropriate given the sample sizes involved.

This comprehensive analytical approach ensures robust interpretation of xenograft data, providing reliable insights into antibody targeting efficiency that can guide further development decisions.

How can DLD-1 cells be utilized in developing antibody-drug conjugates targeting colorectal cancer markers?

DLD-1 cells represent an invaluable platform for developing antibody-drug conjugates (ADCs) targeting colorectal cancer markers. Researchers should implement the following methodological approach to leverage this cell line for ADC development:

Begin by comprehensively profiling DLD-1 cells for expression of potential ADC targets using proteomics, flow cytometry, and immunohistochemistry. Prioritize targets with high expression in DLD-1 cells that also show rapid internalization kinetics, as the search results emphasize that "an ideal target for ADC development should rapidly internalize and traffic to the lysosome for payload release" .

Generate a panel of antibodies against identified targets and characterize their binding kinetics to DLD-1 cells. The search results demonstrate this approach with H231 antibody binding to endogenous EREG on DLD-1 cells with high affinity (Kd = 0.36 μg/ml or 2.4 nmol/L) .

Evaluate antibody internalization using the methodologies described earlier, focusing particularly on lysosomal trafficking which is critical for ADC payload release. Select antibodies with optimal internalization profiles for conjugation to cytotoxic payloads.

Produce ADC candidates using various linker-payload combinations and test their cytotoxicity against DLD-1 cells in vitro. Include controls such as unconjugated antibody and free payload to distinguish the contribution of each component.

Establish DLD-1 xenograft models for in vivo evaluation of promising ADC candidates. Use the immunoPET methodology described in the search results to assess biodistribution and tumor targeting . Follow with efficacy studies measuring tumor growth inhibition and survival.

Generate resistant variants of DLD-1 cells through chronic exposure to increasing ADC concentrations to identify potential resistance mechanisms that might emerge clinically.

This systematic approach utilizing DLD-1 cells throughout the ADC development pipeline enables rational optimization of each component - antibody, linker, and payload - ultimately leading to more effective ADC candidates for colorectal cancer therapy.

What methodological approaches can enhance the study of immune checkpoint inhibitors using DLD-1 cell models?

Enhancing the study of immune checkpoint inhibitors using DLD-1 cell models requires innovative methodological approaches that better recapitulate the complexities of the tumor microenvironment. Researchers should implement the following strategies:

Develop DLD-1 organoid cultures that maintain 3D architecture and heterogeneity more representative of human tumors. These can be established from parental DLD-1 cells or created through genetic modification to express immune checkpoint molecules at physiologically relevant levels.

Engineer DLD-1 cells with inducible expression systems for immune checkpoint molecules like PD-L1. This allows precise control over expression levels and timing, enabling studies on how expression dynamics influence antibody efficacy. The search results indicate that IFNγ treatment upregulates PD-L1 on cancer cells, which could be leveraged in this approach .

Establish advanced co-culture systems that include:

• DLD-1 cells (with defined checkpoint molecule expression)

• Autologous or allogeneic T cells with defined activation states

• Additional components of the tumor microenvironment such as cancer-associated fibroblasts and myeloid cells

The search results describe that "anti-PD-L1:TRAIL converted immunosuppressive PD-L1-expressing myeloid cells into pro-apoptotic effector cells" , highlighting the importance of including myeloid components in model systems.

Implement multiplexed analysis approaches to simultaneously monitor:

• Cancer cell death (Annexin-V staining)

• T cell activation markers (CD69, CD25)

• Cytokine production (IFNγ, mentioned in the search results)

• Changes in immune checkpoint expression

• Immune cell trafficking and spatial distribution

Develop humanized mouse models based on DLD-1 xenografts that incorporate human immune cell components, allowing in vivo evaluation of immune checkpoint inhibitors in a more relevant context.

By implementing these advanced methodological approaches, researchers can generate more predictive data on immune checkpoint inhibitor efficacy and mechanism of action, potentially leading to improved clinical translation of these therapies for colorectal cancer patients.

How can researchers utilize DLD-1 cells to develop novel bifunctional antibodies combining immune activation with direct tumor killing?

DLD-1 cells provide an excellent platform for developing novel bifunctional antibodies that combine immune activation with direct tumor killing. Based on successful approaches with bifunctional constructs like anti-PD-L1:TRAIL, researchers should implement the following comprehensive methodology:

Begin by identifying relevant target pairs on DLD-1 cells - one target should mediate immune regulation (e.g., PD-L1, as mentioned in the search results) while the other should be involved in cell death pathways or growth signaling. For targets not naturally expressed at sufficient levels, generate engineered DLD-1 lines with stable expression.

Design bifunctional antibody constructs following the model described in the search results, where "a new bi-functional fusion protein, designated anti-PD-L1:TRAIL, was constructed comprising a PD-L1-blocking antibody fragment genetically fused to the extracellular domain of the pro-apoptotic tumoricidal protein TRAIL" . Alternative designs could combine immune checkpoint blockers with targeted cytokines, death receptor agonists, or growth factor receptor antagonists.

Evaluate each functional domain separately:

• For immune checkpoint components: assess binding and blocking using competitive binding assays as described earlier

• For direct killing components: measure apoptosis induction through Annexin-V staining, PARP cleavage analysis, or caspase activation assays

Implement co-culture systems with immune effector cells to evaluate the bifunctional antibody's activity in a more complex setting. As described in the search results, mix DLD-1 cells with PBMCs or T cells at various E:T ratios, treat with the bifunctional antibody, and assess both tumor cell death and immune cell activation .

Analyze functional synergy by comparing the activity of the bifunctional antibody to equivalent concentrations of its individual components alone or in combination. The search results highlight this synergy, noting that "anti-PD-L1:TRAIL converted immunosuppressive PD-L1-expressing myeloid cells into pro-apoptotic effector cells that triggered TRAIL-mediated cancer cell death" .

Test the bifunctional antibody in DLD-1 xenograft models, initially using immunodeficient mice to assess direct killing effects, then in humanized models to evaluate the immune-activating component.

This comprehensive approach enables the development of bifunctional antibodies with "multi-fold and mutually reinforcing anticancer activity" , potentially offering more effective therapeutic options for colorectal cancer patients.